benazepril

Benazepril is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat high blood pressure (hypertension), either alone or in combination with other antihypertensive agents. It is a prodrug that, after oral administration, is hydrolyzed in the liver to its active metabolite benazeprilat. Benazeprilat competitively inhibits ACE, preventing the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor—thereby reducing vascular resistance and lowering blood pressure. Inhibition of ACE also decreases aldosterone secretion and increases plasma renin activity. Additionally, benazeprilat inhibits the degradation of bradykinin, contributing further to vasodilation. Benazepril was developed by Ciba-Geigy (now part of Novartis) and was first approved for use in 1991[2][7]. It is available as tablets for oral administration and has been widely adopted globally for hypertension management; it may also be used off-label or in combination products for heart failure[1][4][5].

Brand names

Lotensin

Other names

苯那普利贝那普利Benazepril Hydrochloride